PATENT-1 and -2
PATENT-1 was a 12-week, double-blind, randomized Phase III study that enrolled 443 patients with pulmonary arterial hypertension (PAH). Patients were randomly assigned (4:2:1) to riociguat individually dose adjusted according to tolerability up to 2.5 mg three times daily (tid), placebo, or riociguat 1.5 mg tid (exploratory dose). The primary endpoint was change from baseline to Week 12 in 6-minute walking distance (6MWD). After completing PATENT-1, eligible patients were invited to participate in an open-label extension study, PATENT-2. All patients in PATENT-2 received riociguat individually adjusted up to 2.5 mg tid in an 8-week blinded phase (the former riociguat 2.5 mg-maximum arm underwent sham titration), followed by an open-label study phase that will continue until all patients transition to the commercially available drug.
CHEST-1 and -2
CHEST-1 was a 16-week, double-blind, randomized Phase III study that enrolled 261 patients with chronic thromboembolic pulmonary hypertension (CTEPH). Patients were excluded if they had received an endothelin-receptor antagonist, prostacyclin analog, phosphodiesterase type 5 inhibitor, or nitric oxide donor within the 3 months before study entry. Patients were randomly assigned (2:1) to riociguat, individually adjusted according to tolerability up to 2.5 mg tid, or placebo. The primary endpoint was change from baseline to Week 16 in 6MWD. After completing CHEST-1, eligible patients were invited to participate in an open-label extension study, CHEST-2. All patients in CHEST-2 received riociguat individually adjusted up to 2.5 mg tid in an 8-week blinded phase (the former riociguat arm underwent sham titration), followed by an open-label study phase that that will continue until all patients transition to the commercially available drug.
Cox Proportional Hazards Analyses
Cox proportional hazards analyses were undertaken in patients who were receiving riociguat (2.5 mg tid-maximum) in PATENT-1/CHEST-1, and went on to participate in PATENT-2/CHEST-2.
The Cox proportional hazards analyses performed assessed the change in risk of death or clinical worsening in patients achieving ≥1 low-risk criteria, compared with those achieving none (according to the French registry methods), and the number of patients achieving a low-risk stratum, compared with those achieving an intermediate-risk stratum (according to the Swedish/COMPERA method). Due to no or few events in some risk groups/strata, hazards ratios could not be calculated in some cases.
Analyses were based on observed cases without imputation. Only patients receiving riociguat 2.5 mg tid-maximum in PATENT-1 who participated in PATENT-2 were considered in this analysis. Figure E1 . Kaplan-Meier curves for survival in patients based on risk stratification at
